Novo Nordisk receives FDA approval for Norditropin® FlexPro® for growth hormone treatment

Novo NordiskNovo Nordisk announced that the US Food and Drug Administration (FDA) has approved Norditropin® FlexPro®, a new prefilled growth hormone injection pen to be used by children and adults.

Norditropin® FlexPro® has a unique new dosing mechanism, a user-friendly design which makes it easy to learn and use, and an audible click that confirms that the dose has been delivered. Norditropin® FlexPro® requires no reconstitution and no loading of cartridges. Norditropin® FlexPro® is available in 5 mg/1.5 ml, 10 mg/1.5 ml and 15 mg/1.5 ml pens.

In a handling study[1], 100% of patients found it easy to learn how to use Norditropin® FlexPro®. Ninety-nine percent of patients found it easy to push the button to dose, and 97% felt confident the correct dose was delivered.

"During our 20 years providing Norditropin® growth hormone, we have listened to patients and we understand the importance of providing simple, hassle-free patient care," says Pablo de Mora, global vice president of Growth Hormone Treatment in Novo Nordisk. "With the advantages of our new Norditropin® FlexPro® we are convinced that daily injections will be made even simpler, so patients are better able to achieve their individual treatment goals."

Novo Nordisk introduced Norditropin® in 1988; the first liquid growth hormone formulation, Norditropin® SimpleXx®, in 1999; and the first prefilled growth hormone pen, Norditropin NordiFlex®, in 2004. The introduction of Norditropin® FlexPro® represents the latest advance in growth hormone pens building on this heritage.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.com.

1. Fuchs GS et al. Clin Ther 2009; 31 (12)

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]